



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection

Steven Fishbane, Jamie S. Hirsch, and Vinay Nair



Novel Agents for the Treatment of Coronavirus Disease 2019

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been historic in terms of the number of lives tragically affected and the huge toll of morbidity and mortality.¹ During the pandemic's first year there were many drugs employed and formally studied, with at best modest clinical benefits.² In mid-2021, results of studies with 2 new drugs brought substantial new hope. Merck and Ridgeback Biotherapeutics' drug, molnupiravir, was reported to reduce death and hospitalization from coronavirus disease 2019 (COVID-19) by 30%.³ Soon after this, Pfizer reported impressive results for its drug, Paxlovid. In this report we will discuss the latter drug and why, despite its great efficacy, it may pose a major safety risk to transplant patients and others treated with calcineurin inhibitors (CNIs) or mTOR (mammalian target of rapamycin) inhibitors.

Paxlovid is a combination of 2 oral drugs. The first, nirmatrelvir (PF-07321332), is a newly developed agent that blocks the SARS-CoV-2 3CL protease, which is important for viral replication. The second drug is ritonavir, which is used only to slow nirmatrelvir metabolism.⁴ The EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) Study is evaluating the efficacy and safety of Paxlovid administered twice daily for 5 days as treatment of adults with acute COVID-19.⁵ It is a placebo-controlled, double-blind study of patients who are at increased risk of developing severe COVID-19 illness. On November 5, 2021, Pfizer announced results of a scheduled interim analysis of the study.⁴ The results were dramatic, with an 89% reduction in risk of hospitalization or all-cause mortality compared to placebo. Among patients treated within the first 3 days of symptoms, by day 28 of follow-up, 3 of 389 were hospitalized—with no deaths—in the Paxlovid group, compared to 27 of 385 hospitalized and 7 deaths in the placebo group ($P < 0.0001$). These positive results led the study's data monitoring committee, in consultation with the US Food and Drug Administration (FDA), to recommend cessation of further study enrollment (at the time of writing the study continues with existing participants).⁴ On November 16, 2021, the company applied for an emergency use authorization (EUA) from the FDA. On December 14, 2021, Pfizer provided additional information, indicating that “in vitro data confirm that nirmatrelvir is a potent inhibitor of the Omicron 3CL protease... indicat[ing] nirmatrelvir's potential to maintain robust

antiviral activity against Omicron.”⁶ On December 22, 2021, Paxlovid received an EUA from the FDA.⁷ Importantly, the EUA includes a contraindication statement for patients on drugs that are “highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions.”⁸ The list of contraindicated drugs, however, does not include cyclosporine, tacrolimus, or sirolimus, or indeed any mention of CNIs or mTOR inhibitors.⁸ Consequently, it is likely that Paxlovid will be prescribed to many transplant patients.

Potential Interactions With Immunosuppressive Agents

While Paxlovid brings great promise to the fight against COVID-19, for transplant patients it causes significant risk related to drug interactions. Generally, patients with transplants are at high risk of COVID-19 morbidity and mortality owing to immunosuppression, lack of response to vaccination, and comorbid conditions.^{9,10} With the current surge of SARS-CoV-2 and the Omicron variant, patients will approach providers seeking Paxlovid prescriptions—which may occur even preemptively, prior to diagnosis of COVID-19. Pfizer stated in a press release, “[Paxlovid] can be prescribed at the first sign of infection or, pending clinical success of the rest of the EPIC development program and subject to regulatory authorization, at first awareness of an exposure.”⁷ Although patients could benefit greatly from Paxlovid, they may be at significant risk for drug interactions and harm owing to the ritonavir component of Paxlovid, a particularly potent inhibitor of cytochrome P450 system CYP3A enzymes.¹¹ The interaction between ritonavir and CYP3A-dependent drugs can result in increases in area under the curve blood concentrations of these latter drugs between 1.8- and 20-fold.¹¹ Because cyclosporine, tacrolimus, and the mTOR inhibitors sirolimus and everolimus are highly dependent on CYP3A metabolism, their plasma levels on exposure to ritonavir will increase substantially and rapidly. This effect has been seen previously in reports involving HIV-positive transplant patients on ritonavir as a single agent, or as part of a combination drug. One report found an increase in tacrolimus trough from 8.7 to 106 ng/mL after only 3 days of starting darunavir/ritonavir, despite a 12% reduction in dose.¹² A tacrolimus trough of this level, even if transient, can lead to dangerous side effects including kidney injury, seizures, PRES (posterior reversible encephalopathy), and even death. In other studies, a

Box 1. Paxlovid in Transplant Patients: Dosing Issues and Risk Mitigation Strategies**Dosing Recommendations**

- Reduce or hold calcineurin inhibitor dose following first dose of Paxlovid
- Base subsequent dosing on trough levels
- If trough below target goal, administer single dose of calcineurin inhibitor
- Resume normal calcineurin inhibitor dose once treatment course of Paxlovid concludes

Note that these are only recommendations and should be individualized based on the ability to obtain immunosuppressive level monitoring, as well as baseline calcineurin inhibitor dose and CYP3A polymorphisms, if known. Similar strategies can be employed for other drugs, including mTOR inhibitors.

Risk Mitigation Strategies*Health Systems:*

- Educational outreach through all applicable channels
- Email notifications and information embedded within other COVID-19 updates
- Partnership outreach to pharmacies alerting them to Paxlovid–calcineurin inhibitor interactions
- Interruptive alerts or other point-of-prescribing notifications embedded within the electronic health record
- Tasking or inbox alerts to prescribing providers
- Automated reports to identify all health system or practice patients on ongoing calcineurin inhibitor therapy who are newly prescribed Paxlovid
- Because of the multiple medications that could be affected by Paxlovid treatment, inclusion of pharmacists in medication management

Nephrologists, Transplant Programs, and Related Providers:

- Identify patients in practice currently treated with calcineurin inhibitors
- Email or other notification to patients
- Discuss potential Paxlovid issues during office visits
- Outreach to referring primary care physicians to inform on Paxlovid drug interactions

reduction of CNI dosage of up to 99%—with tacrolimus doses as low as 0.5 mg once every 7 days—was enough to maintain therapeutic trough levels.^{13–16} The same effect has been noted with sirolimus.¹⁷ It is important to note that in the pivotal EPIC-HR Study, a highly relevant exclusion criterion was “current or expected use of any medications or substances that are highly dependent on CYP3A4 for clearance or are strong inducers of CYP3A4.”⁵

In addition to the interaction between ritonavir and CNIs and mTOR inhibitors, inhibition of CYP3A can result in dangerous interactions with other drugs with which transplant patients are frequently treated, including HMG-CoA reductase inhibitors (statins) as well as calcium channel blockers and anticoagulants such as warfarin. A more detailed list of potential interactions can be referenced in the FDA EUA document.⁸ The effects of Paxlovid on each of these drugs must be considered.

With Paxlovid treatment for COVID-19, the ritonavir dose is relatively low at 100 mg twice daily and treatment is only for 5 days. Despite this limited exposure, risk for transplant patients could still be substantial. The risk is amplified by the availability of Paxlovid coinciding with the Omicron-driven spike in the number of COVID-19 cases. Risk may also be increased because the combined drug is marketed under a single name, Paxlovid, which may result in providers failing to recognize the ritonavir component. Moreover, transplant patients may turn first not to their nephrologists, but to primary care providers who may not be aware of interactions between ritonavir and CNIs or mTOR inhibitors.

Recommendations for Paxlovid Treatment and Risk Mitigation in Transplant Recipients

Although current experience in dose adjustment does not exist, based on existing data with ritonavir we suggest an empirical reduction or withholding of CNI administration after initiation of Paxlovid and basing subsequent CNI dosing on trough drug levels for at least as long as Paxlovid treatment continues. Once Paxlovid treatment concludes, the original dose of CNI may be resumed, but monitoring trough levels for 1 or 2 days seems prudent given the circulating half-life of ritonavir is 3–5 hours and its CYP3A effect could last somewhat longer. The timing of when and how to restart CNIs or mTOR inhibitors should weigh the urgency of restarting against the possibility of residual CYP3A4 inhibition. It is important to note that these recommendations are only suggestions, and dosing strategies should be individualized based on the ability to obtain immunosuppressive level monitoring as well as baseline CNI dose and CYP3A polymorphisms, if known. Finally, above and beyond drug interactions, Paxlovid also requires renal dose adjustment, with dose reduction suggested for an estimated glomerular filtration rate of 30–60 mL/min/1.73 m² (at <30 mL/min/1.73 m², it is not recommended at all).⁸

Given the high risk of drug-drug interaction, hospital and health systems should undertake monitoring and decision support for the use of Paxlovid (Box 1). Like many other forms of patient safety monitoring and drug safety, a multimodal approach is most likely to be effective. We recommend widespread educational outreach through grand rounds and other lectures; email notifications and information embedded within other COVID-19 updates; partnership outreach to local pharmacies alerting them to Paxlovid interactions with CNIs and mTOR inhibitors; interruptive alerts or other point-of-prescribing notifications embedded within the electronic health record; automated inbox or tasking to prescribing providers; and automated reports to identify all health system or practice patients receiving CNIs or mTOR inhibitors on an ongoing basis who are newly prescribed Paxlovid, which would allow proactive patient contact and dose adjustments. Additionally, other therapies for COVID-19 prevention or treatment may be an alternative to Paxlovid and may

mitigate the risks of drug interactions for patients already taking these interacting immunosuppressants. Tixagevimab/cilgavimab (Evusheld) is a monoclonal antibody for pre-exposure prophylaxis for immunocompromised patients, and sotrovimab is a monoclonal antibody for treatment of SARS-CoV-2 infection with efficacy against the Omicron variant.

In conclusion, Paxlovid is a highly promising new drug combination for treatment of COVID-19 that has important safety risks for patients with transplants or kidney disease. Yet, these patients are at higher risk related to COVID-19, and there is a great need for an efficacious new agent like Paxlovid. Clinicians must individualize treatment, determining whether Paxlovid's substantial efficacy outweighs risks in the context of individual patients. When treatment is initiated, caution and vigilance should be maintained and the risk management strategies described above employed as appropriate.

Article Information

Authors' Full Names and Academic Degrees: Steven Fishbane, MD, Jamie S. Hirsch, MD, and Vinay Nair, MD.

Authors' Affiliation: Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra / Northwell, Great Neck, New York.

Address for Correspondence: Steven Fishbane, MD, Northwell Health, 100 Community Dr, Great Neck, NY 11021. Email: sfishbane@northwell.edu

Support: None.

Financial Disclosure: The authors declare that they have no relevant financial interests.

Peer Review: Received December 28, 2021. Evaluated by 2 external peer reviewers, with direct editorial input from an Associate Editor and the Editor-in-Chief. Accepted in revised form January 7, 2022.

Publication Information: © 2022 by the National Kidney Foundation, Inc. Published online January 12, 2022 with doi [10.1053/j.ajkd.2022.01.001](https://doi.org/10.1053/j.ajkd.2022.01.001)

References

1. Worobey M, Pekar J, Larsen BB, et al. The emergence of SARS-CoV-2 in Europe and North America. *Science*. 2020;370(6516):564-570.
2. Crichton ML, Goeminne PC, Tuand K, et al. European Respiratory Society COVID-19 Task Force. The impact of therapeutics on mortality in hospitalised patients with COVID-19: systematic review and meta-analyses informing the European Respiratory Society living guideline. *Eur Respir Rev*. 2021;30(162):210171.
3. Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVE-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19. Accessed December 12, 2021. <https://www.merck.com/news/merck-and-ridgeback-biotherapeutics-provide-update-on-results-from-move-out-study-of-molnupiravir-an-investigational-oral-antiviral-medicine-in-at-risk-adults-with-mild-to-moderate-covid-19/>
4. Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study. Accessed December 21, 2021. <https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate>
5. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19. Accessed December 16, 2021. <https://clinicaltrials.gov/ct2/show/study/NCT04960202?term=EPIC-HR&draw=2&rank=1>
6. Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death. Accessed December 21, 2021. <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results>
7. Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment. Accessed December 22, 2021. [https://www.pfizer.com/news/press-release/press-release-detail/pfizer-receives-us-fda-emergency-use-authorization-novel#:~:text=The%20U.S.%20Food%20and%20Drug%20Administration%20\(FDA\)%20has%20issued%20an,at%20least%2040%20kg\)%20with](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-receives-us-fda-emergency-use-authorization-novel#:~:text=The%20U.S.%20Food%20and%20Drug%20Administration%20(FDA)%20has%20issued%20an,at%20least%2040%20kg)%20with)
8. Fact Sheet for Healthcare Providers: Emergency Use Authorization for PAXLOVIDTM. Accessed December 24, 2021. <https://www.fda.gov/media/155050/download>
9. Nair V, Jandovitz N, Hirsch JS, et al. COVID-19 in kidney transplant recipients. *Am J Transplant*. 2020;20(7):1819-1825.
10. Stock PG, Henrich TJ, Segev DL, Werbel WA. Interpreting and addressing suboptimal immune responses after COVID-19 vaccination in solid-organ transplant recipients. *J Clin Invest*. 2021;131(14):e151178.
11. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. *Clin Pharmacokinet*. 1998;35(4):275-291.
12. Mertz D, Battegay M, Marzolini C, Mayr M. Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus. *Am J Kidney Dis*. 2009;54(1):e1-e4.
13. Jain AB, Venkataramanan R, Eghtesad B, et al. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. *Liver Transpl*. 2003;9(9):954-960.
14. Teicher E, Vincent I, Bonhomme-Faivre L, et al. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. *Clin Pharmacokinet*. 2007;46(11):941-952.
15. Sheikh AM, Wolf DC, Lebovics E, Goldberg R, Horowitz HW. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. *Transplantation*. 1999;68(2):307-309.
16. Izzedine H, Launay-Vacher V, Baumelou A, Deray G. Antiretroviral and immunosuppressive drug-drug interactions: an update. *Kidney Int*. 2004;66(2):532-541.
17. Barau C, Blouin P, Creput C, Taburet AM, Durrbach A, Furlan V. Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient. *Fundam Clin Pharmacol*. 2009;23(4):423-425.